Sintilimab Explained

Type:mab
Cas Number:2072873-06-2
Kegg:D12119
Unii:8FU7FQ8UPK
Synonyms:Anti-PD-1 monoclonal antibody IBI308[1]

Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease,[2] and has been approved in China.[3]

It is a fully human IgG4 monoclonal antibody[4] that binds to programmed cell death protein 1.[5]

It was jointly developed by Innovent Biologics[6] and Eli Lilly.[7]

Medical uses

Sintilimab is medication that is indicated for the treatment of relapsed or refractory classical Hodgkin's lymphoma after failure of at least second-line systemic chemotherapy.[5]

Side effects

Common side effects include fever, thyroid dysfunction, elevation of liver enzymes, and lung inflammation.[8]

Research

Currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors.[9] In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published.[10]

Notes and References

  1. Web site: anti-PD-1 monoclonal antibody IBI308 . 2011-02-02 . NCI Drug Dictionary . .
  2. Web site: Antibody Drug Conjugates Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026. October 24, 2018. Reuters.
  3. Web site: NMPA Approves Tyvyt For Hodgkin's lymphoma Read . January 9, 2019. .
  4. Ying K, Xu N, Jiang H, Liu Y, Zhou H, Wang S . OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer . . Dec 1, 2018. 10.1016/j.jtho.2018.10.018. 2018 . 13 . 12 . S1047 . free .
  5. Hoy SM . Sintilimab: First Global Approval . Drugs . 79 . 3 . 341–346 . February 2019 . 30742278 . 10.1007/s40265-019-1066-z . 59945274 .
  6. Web site: Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company. December 20, 2018. SEC.gov.
  7. Web site: Sintilimab - Eli Lilly/Innovent Biologics . Adis Insight . 28 March 2019 . Springer Nature Switzerland AG .
  8. 2018 ASCO Annual Meeting . A first-in-human phase 1a trial of sintilimab (IBI308). 12 October 2019. American Society of Clinical Oncology.
  9. Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection). Feb 22, 2019 . Innovent Biologics, Inc. . PR NewsWire .
  10. Ansell SM . Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma . The Lancet. Haematology . 6 . 1 . e2–e3 . January 2019 . 30612711 . 10.1016/S2352-3026(18)30210-2 . 58561198 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sintilimab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.